RxDoctor Payments Data

Darlene Rae, MD

Family Medicine · Beaumont, CANPI 1881640373

Payments from drug & device makers

$624in general payments, 2019–2025

Across 26 payments — averaging $23.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$137
  • Novartis$111
  • AstraZeneca$92
  • Astellas Pharma US Inc$64
  • Johnson & Johnson$50
  • GSK$49
  • plus $120 from 7 others

What the payments were for

  • Food & beverage$624100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$624 in reported general payments places this provider in the 65th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$19,878
Medicare patients
105
Services billed
175

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide12$12,362
Breo ElliptaFluticasone/Vilanterol11$6,035
Albuterol Sulfate HfaAlbuterol Sulfate57$1,983
Atorvastatin Calcium118$1,178
Levothyroxine Sodium78$1,160
Venlafaxine Hcl ErVenlafaxine Hcl13$845
Omeprazole41$704
Gabapentin30$652
Losartan Potassium62$635
Donepezil Hcl62$613
Lisinopril71$611
Metoprolol Succinate28$549
Rosuvastatin Calcium40$525
Diltiazem 24hr Er (Cd)Diltiazem Hcl22$509
Tamsulosin Hcl52$502

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$137$12,36212 claims
GSKBreo Ellipta$49$6,03511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 10,533 family medicine providers in California.

Other family medicine in Beaumont

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →